To study on the effect of clinical pathway （CP） on controlling pharmaceutical costs, we selected complex, chronic, non-communicable diseases, including cerebral infarction, cerebral hemorrhage, transient ischemic at...To study on the effect of clinical pathway （CP） on controlling pharmaceutical costs, we selected complex, chronic, non-communicable diseases, including cerebral infarction, cerebral hemorrhage, transient ischemic attack, and chronic obstructive pulmonary disease, as diseases to implement clinical pathways at a tertiary hospital in Qingdao. We then conducted intermittent time series analysis on pharmaceutical costs. After the implementation of clinical pathway, overall pharmaceutical costs of patients with transient ischemic attack reduced significantly. The effect was not significant for cerebral hemorrhage patients. The implementation of clinical pathway has a desirable outcome on controlling pharmaceutical costs.展开更多
Under Chinese medicine and health care system, Medicine Catalogue for National Basic Medical Insurance（2009） was issued in 2009 in China to fulfill the basic drug demands of the insured Chinese and to control the me...Under Chinese medicine and health care system, Medicine Catalogue for National Basic Medical Insurance（2009） was issued in 2009 in China to fulfill the basic drug demands of the insured Chinese and to control the medical expenses. In this study, the influence of the list adjustment on drug utilization was investigated. With the comparison between inpatients＇ use of drugs before and after adjustment of Basic Medical Insurance Drug List, we classified the drugs adjusted in national list into six categories： class A to class B, class B to class A, class A to class C, class B to class C, class C to class A, and class C to class B（class A referring to overall insured drugs, class B referring to partial reimbursement drugs, class C referring to self-funded drugs in China）, and drug utilization and expenditure were analyzed with time series model. We analyzed the overall expenditure and average expenditure per 10 000 people based on the comparison before and after the adjustment of 2009 Basic Medical Insurance Drug List. The drug expenditure from class A to class B was decreased by 13.87% of overall expenditure and 16.37% of average expenditure per 10 000 people, and it was decreased by 38.74% and 48.03% from class A to class C; respectively, the drug expenditure from class B to class A was increased by 74.12% and 94.52%, while it was reduced by 19.79% and 14.52% from class B to class C; expenditure declined by 31.77% and 36.22% from class C to class A, and expenditure was increased by 12.42% and 22.05% from class C to class B, respectively, both were lower than before. The adjustment of National Basic Medical Insurance Drug List reduced the overall drug expenditure.展开更多
文摘To study on the effect of clinical pathway （CP） on controlling pharmaceutical costs, we selected complex, chronic, non-communicable diseases, including cerebral infarction, cerebral hemorrhage, transient ischemic attack, and chronic obstructive pulmonary disease, as diseases to implement clinical pathways at a tertiary hospital in Qingdao. We then conducted intermittent time series analysis on pharmaceutical costs. After the implementation of clinical pathway, overall pharmaceutical costs of patients with transient ischemic attack reduced significantly. The effect was not significant for cerebral hemorrhage patients. The implementation of clinical pathway has a desirable outcome on controlling pharmaceutical costs.
文摘Under Chinese medicine and health care system, Medicine Catalogue for National Basic Medical Insurance（2009） was issued in 2009 in China to fulfill the basic drug demands of the insured Chinese and to control the medical expenses. In this study, the influence of the list adjustment on drug utilization was investigated. With the comparison between inpatients＇ use of drugs before and after adjustment of Basic Medical Insurance Drug List, we classified the drugs adjusted in national list into six categories： class A to class B, class B to class A, class A to class C, class B to class C, class C to class A, and class C to class B（class A referring to overall insured drugs, class B referring to partial reimbursement drugs, class C referring to self-funded drugs in China）, and drug utilization and expenditure were analyzed with time series model. We analyzed the overall expenditure and average expenditure per 10 000 people based on the comparison before and after the adjustment of 2009 Basic Medical Insurance Drug List. The drug expenditure from class A to class B was decreased by 13.87% of overall expenditure and 16.37% of average expenditure per 10 000 people, and it was decreased by 38.74% and 48.03% from class A to class C; respectively, the drug expenditure from class B to class A was increased by 74.12% and 94.52%, while it was reduced by 19.79% and 14.52% from class B to class C; expenditure declined by 31.77% and 36.22% from class C to class A, and expenditure was increased by 12.42% and 22.05% from class C to class B, respectively, both were lower than before. The adjustment of National Basic Medical Insurance Drug List reduced the overall drug expenditure.
